Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

STATUS

Recruiting
End date

Mar 28, 2025
participants needed

90
sponsor

Swiss Group for Clinical Cancer Research

Send

Updated on 19 February 2024

See if I qualify

cancer

blood transfusion

platelet count

renal function

measurable disease

gilbert's syndrome

neutrophil count

lung cancer

treatment regimen

durvalumab

vaccination

pulmonary function tests

carcinoma

immunomodulators

pulmonary function test

stage iii non-small cell lung cancer

adjuvant therapy

pet/ct scan

kidney function test

adjuvant chemotherapy

large cell carcinoma

pneumonectomy

complete excision

combined modality therapy

adjuvant

non-small cell lung cancer

ct scan with contrast

small cell lung cancer

Summary

Resectable, locally advanced NSCLC with involvement of mediastinal lymph nodes (N2) is associated with a high risk of (systemic) recurrence despite neo-adjuvant chemotherapy. Neo-adjuvant immunotherapy is a promising additional treatment modality aiming at increasing local control and better tackling micrometastases at the time of radical local treatment. Radiotherapy is thought to act synergistically with immunotherapy through release of tumor antigens and modulation of the local immune microenvironment in favor of a better antigen-presentation and (systemic) anti-tumor immune response (abscopal effect).

The aim of the proposed SAKK 16/18 trial is to evaluate the efficacy and safety of adding immune-modulatory radiotherapy to the SAKK 16/14 treatment regimen by combining neo-adjuvant radio-immunotherapy. Due to the lack of evidence for an optimal radiotherapy regimen for an "in-situ vaccination" effect three different radiotherapy regimens will be tested.

Description

In resectable locally advanced lung cancer there is an urgent need for more efficacious therapy, since most of the patients will eventually have a relapse and will die of the disease. Distant metastases are the main site of recurrence. Therefore, the most promising treatment strategy is to better eliminate micrometastases present at the time of diagnosis through improved systemic treatment. In this regard, the SAKK 16/14 trial is investigating the efficacy of the anti-PD-L1 inhibitor durvalumab before and after surgery added to standard neoadjuvant chemotherapy with cisplatin/docetaxel. It has just completed accrual as of Q1 2019.

The primary aim of the SAKK 16/18 trial is to evaluate the efficacy and safety of adding immune-modulatory radiotherapy to the SAKK 16/14 treatment regimen by combining it with neoadjuvant immunotherapy. Due to the lack of evidence for an optimal immune-modulatory radiotherapy regimen we test 3 different radiotherapy regimens to investigate differences in efficacy and tolerability as key exploratory endpoint.

Neoadjuvant therapy is the optimal setting to test the combination of immune-modulatory radiotherapy and immune checkpoint inhibitor therapy. Resection of the primary tumor and mediastinal lymph nodes will allow to investigate pathological responses and nodal downstaging at an early time point. Furthermore, this setting allows for extensive translational research evaluating cellular and molecular mechanisms of anti-tumor immune response.

SAKK 16/18 is a prospective, multicenter, phase II trial with 3 radiotherapy cohorts.

The treatment consists of

Neoadjuvant chemotherapy with cisplatin and docetaxel: 3 cycles of 21 days
Neoadjuvant immunotherapy with durvalumab: 1 cycle
Neoadjuvant immune-modulatory radiotherapy
Concurrent with neoadjuvant immunotherapy
Random assignment to one of the following fractionation regimens:
20x2 Gy (weekdaily, 4 weeks)
5x5 Gy (weekdaily, 1 week)
3x8 Gy (on alternate days, 1 week)
Surgery
- Between 4 and 6 weeks after the application of durvalumab (independent of the radiotherapy regimen)
If indicated: Postoperative radiotherapy (should start between 3 to 6 weeks after surgery)
Adjuvant immunotherapy with durvalumab: 13 cycles of 28 days

Details

Condition	Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer
Age	18-75 years
Treatment	Radiotherapy, Durvalumab
Clinical Study Identifier	NCT04245514
Sponsor	Swiss Group for Clinical Cancer Research
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Written informed consent according to ICH-GCP regulations before registration and prior to any trial specific procedures
	Histologically (cytology is accepted if histology is not possible) confirmed NSCLC (adeno-, squamous-, large cell carcinoma, or NSCLC not otherwise specified (NOS)) irrespective of genomic aberrations or PD-L1 expression status
	Tumor stage T1-4>7 N2 M0 (i.e. T1-3 N2 or T4 N2 but T4 only allowed if due to size > 7cm, not allowed if due to invasion or nodule in different ipsilateral lobe), according to the TNM classification, 8th edition, December 2016 (see Appendix 2). Mediastinal lymph node staging has to follow the process chart
	Tumor is considered resectable based on a multidisciplinary tumor board decision made before neoadjuvant treatment. Resectable is when a complete resection can be achieved according to Rami-Porta
	Patients with a prior malignancy (except NSCLC) and treated with curative intention are eligible if all treatment of that malignancy was completed at least 2 years before registration and the patient has no evidence of disease at registration. Less than 2 years is acceptable for malignancies with low risk of recurrence and/or no late recurrence, after consultation with CI
	Measurable disease per RECIST v1.1 criteria by PET/CT with contrast enhanced CT-scan
	Tumor tissue is available for the mandatory translational research (formalin-fixed; preferably histology, cytology allowed if histology is not possible)
	Age 18-75 years at time of registration
	WHO performance status 0-1
	Adequate bone marrow function: absolute neutrophil count 1.5 x 109/L, platelet count 100 x 109/L, hemoglobin 90 g/L (transfusion allowed)
	Adequate hepatic function: total bilirubin 1.5 x ULN (except for patients with Gilbert's disease 3.0 x ULN), AST and ALT 1.5 x ULN, AP 2.5 x ULN
	Adequate renal function: calculated creatinine clearance 60 mL/min, according to the formula of Cockcroft-Gault
	Appropriate lung function based on the ESTS guidelines
	For pneumonectomy: FEV1 and DLCO 80%. If one of both <80%, an exercise test peak VO2 >75% or 20ml/kg/min is needed
	For resection less than pneumonectomy (resection up to the calculated extent): exercise test peak VO2 35% or 10ml/kg/min, with predicted postoperative FEV1 and DLCO 30%
	Adequate cardiac function according to investigator's decision based on evaluation of risk according to NYHA classification
	Women of childbearing potential must use highly effective contraception, are not pregnant or lactating and agree not to become pregnant during trial treatment and until 90 days after the last dose of investigational drug. A negative pregnancy test performed within 7 days before registration is required for all women of childbearing potential
	Men agree not to donate sperm or to father a child during trial treatment and until 90 days after the last dose of investigational drug
Exclusion Criteria
	Presence of any distant metastasis or N3 disease. Brain metastases have to be excluded by CT or MRI
	Sulcus superior tumors (Pancoast tumors) or T4 for any other reason than size >7cm
	Any previous treatment for NSCLC
	Any previous treatment with immune checkpoint inhibitors, including durvalumab
	Previous radiotherapy to the chest (with the exception of tangential breast irradiation with minimal dose to lung and mediastinum, and superficial orthovoltage or electron irradiation of localized skin lesions)
	Concomitant or recent (within 30 days of registration) treatment with any other experimental drug and/or enrollment in another clinical trial
	Concomitant use of other anti-cancer drugs or radiotherapy
	Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV) unstable angina pectoris, history of myocardial infarction within the last three months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia), uncontrolled hypertension
	Preexisting peripheral neuropathy (> Grade 1)
	Body weight less than 30 kg
	Known history of human immunodeficiency virus (HIV) or active chronic Hepatitis C or Hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous (iv) antimicrobial treatment
	Known history of allogeneic organ transplant
	Active autoimmune disease or a syndrome requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease. Exceptions: vitiligo, resolved childhood asthma/atopy, hypothyroidism stable on hormone replacement, Sjgren's syndrome
	Active or prior documented inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis)
	Concomitant or prior use of immunosuppressive medication within 28 days before registration, with the exceptions of intranasal and inhaled corticosteroids, or systemic corticosteroids which must not exceed 10 mg/day of prednisone or a dose equivalent corticosteroid, and the premedication for chemotherapy
	Any concomitant drugs contraindicated for use with the trial drugs according to the approved product information
	Known hypersensitivity to trial drugs (cisplatin and docetaxel, durvalumab) or to any excipient
	Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

pulmonary function tests

carcinoma

immunomodulators

pulmonary function test

stage iii non-small cell lung cancer

adjuvant therapy

pet/ct scan

kidney function test

adjuvant chemotherapy

large cell carcinoma

pneumonectomy

complete excision

combined modality therapy

adjuvant

non-small cell lung cancer

ct scan with contrast

small cell lung cancer

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)